NRSN
Neurosense Therapeutics Ltd
NASDAQ: NRSN · HEALTHCARE · BIOTECHNOLOGY
$0.48
-13.99% today
Updated 2026-07-29
Market cap
$21.19M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.43
Dividend yield
—
52W range
$1 – $2
Volume
0.2M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.0
Quality
C3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-102.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$6.50
+1253.60%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
No price data available
Stock snapshot
Strengths
+ Debt/equity -0.11x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -102.82 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1.84M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Net income | $-12.34M | $-10.11M | $-10.21M | $-11.13M | $-3.21M |
| EPS | — | — | — | — | $-0.43 |
| Free cash flow | $-7.66M | $-8.38M | $-10.14M | $-7.68M | $-1.84M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Neurosense Therapeutics Ltd trades at $0.48. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -102.82, it sits in the distress.
Frequently asked questions
What is Neurosense Therapeutics Ltd's stock price?
Neurosense Therapeutics Ltd (NRSN) trades at $0.48.
Is Neurosense Therapeutics Ltd overvalued?
Neurosense Therapeutics Ltd carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Neurosense Therapeutics Ltd (NRSN)?
The 12-month analyst consensus target is $6.50, about 1253.6% above the current $0.48. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Neurosense Therapeutics Ltd's Altman Z-Score is -102.82, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-2,175.00%
Beta1.56
50D MA$0.75
200D MA$0.89
Shares out0.04B
Float0.02B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—